Enable AccessibilityEnable Accessibility

Takeda to present four company-sponsored abstracts at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders 2022

At this year’s virtual European Association for Haemophilia and Allied Disorders (EAHAD) congress (Feb. 2-4, 2022), we are sharing four abstracts. Abstracts posters: PO050, PO045, PO105 and PO120 can be found here.

Highlights of data to be presented include:

Abstract Poster Number


Presenting Author


Abstract PO050  

Efficacy and Safety of Rurioctocog Alfa Pegol in Perioperative  Management: Interim Results from An Open-Label  Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia A



Flora Peyvandi

Abstract PO045

Clinical Outcomes Following Prophylaxis with Rurioctocog Alfa Pegol in Patients  with Hemophilia A: Real World Observational Data from the AHEAD International Study


Margareth Ozelo

Abstract PO105

Pharmacokinetic-Guided Prophylaxis with Recombinant Antihemophilic Factor Improves Bleeding Rates in Patients with Moderate Hemophilia: Real-World Observational Data from the AHEAD German Study



Robert Klamroth


Abstract PO120

Safety And Effectiveness Of Recombinant B-Domain–Deleted Porcine-Sequence Factor Viii For Acquired Hemophilia A In A Real-World Setting


Wolfgang Miesbach